Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy" to "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Comparative Efficacy") |
Warner-admin (talk | contribs) m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy") |
||
Line 33: | Line 33: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ Ji et al. 2015 (SWOG S9005)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ Ji et al. 2015 (SWOG S9005)] |
Revision as of 19:05, 13 June 2019
Section editor | |
---|---|
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Ji et al. 2015 (SWOG S9005) | Phase III (C) | Mifepristone | Seems not superior |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed